ERBB2 and neoplasm: Although a difference in grading was obtained in the different subgroups, most TNBC patients (42/51; 82%) and HR−/HER2 + patients (8/10; 80%) had grade III tumours whereas most of the HR+/HER2− patients had a grade II tumour (10/14; 71%), respectively.